Recombinant ITGAL (Efalizumab Biosimilar) antibody
Quick Overview for Recombinant ITGAL (Efalizumab Biosimilar) antibody (ABIN7795106)
Target
Antibody Type
Reactivity
Host
Clonality
Conjugate
Application
Grade
-
-
Expression System
- Mammalian cells
-
Purpose
- Efalizumab Biosimilar, CD11a Monoclonal Antibody
-
Characteristics
- Efalizumab Biosimilar uses the same protein sequences as the therapeutic antibody efalizumab. Efalizumab is a monoclonal anti-CD11a antibody used to treat moderate to severe plaque psoriasis. Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. Efalizumab binds to CD11a, a subunit of leukocyte function antigen-1 (LFA-1), which is expressed on all leukocytes. As a result efalizumab decreases cell surface expression of CD11a.
-
Purification
- Protein A or G affinity column
-
Purity
- >95 % by reducing SDS-PAGE
-
Endotoxin Level
- < 1 EU per 1 mg of the protein by the LAL method
-
Immunogen
- Human CD11a
-
-
anti-ITGAL (Efalizumab Biosimilar) antibody
Reactivity: Human FACS, BR Host: Rabbit Chimeric hu1124 unconjugated Recombinant Antibody
anti-ITGAL (Efalizumab Biosimilar) antibodyReactivity: Human FACS, BR Host: Human Monoclonal hu1124 unconjugated Recombinant Antibody
-
-
Application Notes
- Optimal working dilution should be determined by the investigator.
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- > 3 mg/mL
-
Storage
- 4 °C,-20 °C
-
Storage Comment
- Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.
-
-
- ITGAL (Efalizumab Biosimilar)
-
Alternative Name
- Efalizumab Biosimilar
-
Target Type
- Biosimilar
Target
-
